Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life Sciences to develop an AI cancer vaccine research and development (R&D) platform. The collaboration aims to leverage the respective strengths of both companies to advance the development of AI-driven cancer vaccines. Financial details of the partnership were not disclosed.
Platform Overview
Based on XtalPi’s intelligent computing, expert experience, and automated experiments, the AI cancer vaccine R&D platform will utilize advanced AI algorithms and precise molecular modeling to predict and design diversified cancer vaccines. These vaccines are intended to activate specific immune responses and kill tumors. The platform will screen and verify these vaccines through automated experiments and optimize their activity and pharmaceutics by integrating algorithm feedback and iteration. The ultimate goal is to develop a cancer vaccine with strong immune activity that meets preclinical candidate compound requirements.
Market and Development Context
Statistics show that 20 million new cancer patients were diagnosed globally in 2021, with 4.5 million in China alone. Specific cancer vaccines are designed based on different tumor neoantigens, tumor-associated antigens (TAA), and tumor-specific antigens (TSA) to trigger specific immune responses in patients and achieve immunotherapy goals. Approved therapeutic cancer vaccines include sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, along with preventive vaccines for human papillomavirus (HPV) and hepatitis B virus (HBV). The global cancer vaccine market, valued at USD 6.79 billion in 2021, is projected to reach USD 11.72 billion by 2026, growing at a compound annual rate of 11.53%.-Fineline Info & Tech
